7-0-Benzoylpyripyropene A (7-0-BzP), a semi-synthetic analog of pyripyropene, was investigated for its reversing effect on multidrug-resistant (MDR) tumor cells. 7-0-BzP (6.25 /ig/ml) completely reversed resistance against vincristine and adriamycin in vincristineresistant KB cells (VJ-300) and adriamycin-resistant P388 cells (P388/ADR), respectively. 1-0-BzP alone had no effect on the growth of drug sensitive and drug-resistant cells. 7-0-BzP (6.25 /ig/ml) significantly enhanced accumulation of [3H]vincristine in VJ-300 cells and completely inhibited the binding of [3H]azidopine to the P-glycoprotein in VJ-300 cells and P388/ADRcells. The result suggests that 7-0-BzP effectively reverses P-glycoprotein-related MDRby interacting directly with P-glycoprotein in drug resistant VJ-300 and P388/ADR cells.
(6.25 /ig/ml) completely reversed resistance against vincristine and adriamycin in vincristineresistant KB cells (VJ-300) and adriamycin-resistant P388 cells (P388/ADR), respectively. 1-0-BzP alone had no effect on the growth of drug sensitive and drug-resistant cells. 7-0-BzP (6.25 /ig/ml) significantly enhanced accumulation of [3H]vincristine in VJ-300 cells and completely inhibited the binding of [3H]azidopine to the P-glycoprotein in VJ-300 cells and P388/ADRcells. The result suggests that 7-0-BzP effectively reverses P-glycoprotein-related MDRby interacting directly with P-glycoprotein in drug resistant VJ-300 and P388/ADR cells. Intrinsic or acquired resistance of tumor cells to anticancer drugs remains a serious impediment in the chemotherapy of cancer. Once tumor cells acquire resistance to an antitumor agent, they generally show cross-resistance to a wide variety of structurally and mechanistically unrelated antitumor agents1~3). This multidrug resistance of tumor cells often involves the expression of P-glycoprotein, which is an ATP-dependent drug pump that can exclude a broad range of commonly used chemotheraputic drugs4~6). Recently, both Pglycoprotein and the resulting multidrug resistance (MDR)
phenotype were found to be inhibited by a variety of pharmacological products7M 1). However, the mechanisms by which these agents reverse MDRis not fully understood, and these agents have not been widely applied as chemosensitizing agents for the treatment of cancer because of their toxicity and/or low efficacy. As a part of our search for new modulators of MDR, we pyripyropenes were originally isolated as potent inhibitors of acyl-COA: cholesterol acyltransferase (ACAT) by our group12~14), and 7-O-BzP were recently synthesized as one of the derivatives15'16).
Here we report the enhancement of sensitivity of VJ-300 cells and P388/ADR cells to vincristine or adriamycin by 7-0-BzP.
Materials and Methods
Drugs 7-O-Benzoylpyripyropene A (7-O-BzP) was prepared as described previously15 '16 (5 /ig/ml). At various intervals, the amount of intracellular OCT. 2000 [3H]vincristine was determined as described by Sugimoto et al.20\ In brief, 0.3 ml aliquots were transferred onto an oil layer (0.5 ml) consisting ofToray Silicon SH550 and oil paraffin (4 : 1) in a 1.5 ml microtube. After centrifugation, the supernatant fluid wasremoved.Thecells comprising the pellet were then lysed with 0.3 ml of 0.5 N KOHand the radioactivity was counted by liquid scintillation system. Photolabeled membranes were analyzed by SDS-PAGEon 5-20% gradient gels by a modification of the method of Laemmli22). A total 50 /ig of protein was loaded onto each lane. The gel was fixed in a mixture of 25%isopropyl alcohol and 10%acetic acid, treated with the fluorographic reagent amplify (Amersham Japan, Ltd.) for 30 minutes, dried, and then exposed for 14 days at -70°C using Kodac XAR-5 film.
Results and Discussion

Enhancement of Sensitivity of MDRTumor Cells to Drugs by 7-O-BzP
Weexamined the effect of 7-O-BzP on the sensitivity of KB-3-1-4 and VJ-300 cells to vincristine and of P388/S and P388/ADR cells to adriamycin. The IC50 values of vincristine for KB-3-1-4 and VJ-300 cells were 8.5 ng/ml and 2.8^g/ml, respectively, in the absence of 7-O-BzP (Fig.  2) . The sensitivity to vincristine was enhanced 700-fold by 6.25^g/ml of 7-O-BzP in VJ-300 cells with the IC50 value of vincristine being 4.0ng/ml (Fig. 2B) Adriamycin-sensitive P388/S cells (A) and -resistant P388/ADR cells (B) were treated in triplicate with graded concentrations of adriamycin in the absence (control) or presence of 7-0-BzR for P388/S and P388/ADR cells were 7.0ng/ml and 0.6 fig/m\, respectively, in the absence of 7-0-BzP (Fig. 3) . The sensitivity to adriamycin was enhanced 30-fold by 6.25jUg/ml of 7-O-BzP in P388/ADR cells and the IC50 value of adriamycin being 18.0ng/ml ( On the other hand, the IC50 values of vincristine and adriamycin decreased only 2.3-fold by 6.25^g/ml of 7-O-BzP in KB-3-1-4 cells and P388/S cells ( Fig. 2A and Fig. 3A) .
Previously, we reported the circumvention of MDR of two new compounds, andrastin A9) and kopsiflorine1^. (5^g/ml) in VJ-300 cells (Fig. 4B) . This result suggests that the potentiating effect of cytotoxicity in VJ-300 cells (Fig. 2B) (Fig. 5) . On the other hand, 7-O-BzP was firstly synthesized as an inhibitor of ACAT(IC50: 85 ng/ml) in vitro but it has no effect on this cellular model (data not shown). Furthermore, the structure-activity relationships of pyripyropene analogs between inhibition effect of ACAT and reversal effect of MDR was not corresponded29T
herefore it was regarded that ACAT and P-glycoprotein function may not be related. These results suggest that the reversal effect of 7-0-BzP on MDRtumor cells is due to at least its direct interaction with P-glycoprotein.
The resulting increase in cellular accumulation of anti-cancer drugs lead to a high cytotoxic p otency.
